Apellis Pharmaceuticals submitted a new drug application to the FDA for intravitreal pegcetacoplan, a targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release.
The submission is based on the results of the phase 3 DERBY and OAKS studies, as well as the phase 2 FILLY study. Pegcetacoplan demonstrated reduction in geographic atrophy (GA) lesion growth in more than 1,500 participants with treatment both monthly and every other month. The therapy also had a favorable safety profile in the studies.
“Pegcetacoplan is